Understand the source comparison
Best Peptides to Fix Leaky Gut Ranked: Evidence Comparison
BPC-157 Growth factor upregulation (VEGF, EGFR), angiogenesis acceleration Direct increase in occludin, claudin-1, ZO-1 expression Preclinical only (animal models) 250–500 mcg subQ daily Strongest preclinical evidence for direct barrier repair; no human permea
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Growth factor upregulation (VEGF, EGFR), angiogenesis acceleration
- Direct increase in occludin, claudin-1, ZO-1 expression
- Preclinical only (animal models)
- 250–500 mcg subQ daily
- Strongest preclinical evidence for direct barrier repair; no human permeability trials yet
- Larazotide Acetate
- Zonulin receptor antagonist, EGFR pathway modulation
- Prevents zonulin-mediated tight junction opening
- Phase 3 (celiac disease)
- 0.5mg oral TID
- Only peptide with Phase 3 data for permeability; mechanism specific to zonulin-driven dysfunction
- KPV
- NF-κB inhibition, cytokine suppression (TNF-α, IL-6, IL-1β)
- No direct tight junction effect; reduces inflammation that degrades junctions
- Phase 2 (IBD models)
- 1–5mg oral or subQ daily
- Potent anti-inflammatory; best as adjunct to barrier repair agents rather than standalone
- Thymosin Alpha-1
- T-regulatory cell enhancement, Th17 suppression
- Indirect via immune modulation; no direct epithelial action
- Phase 2 (hepatitis, cancer)
- 1.6mg subQ twice weekly
- Most effective in autoimmune-driven permeability; minimal benefit in non-immune etiologies